Search

Mobile apps are now a $5 trillion industry, and that’s been a boon for mobile app stocks. These two app stocks have gotten the biggest boost of late.

Red flags warning of a stock market decline suddenly abound. And because of those red flags I have recommended almost no new buying. Here’s what I’m seeing.

Apple (AAPL) has had a rough go of late. Is the worst over, or does the stock have further to fall? These two AAPL options trades play both sides.

Alexion Pharmaceuticals (ALXN) receives drug approval, Ameriprise (AMP) and XL Group (XL) report third-quarter results, and ratings changes on two of our stocks.

Thanks to Apple, Qualcomm stock (QCOM) just jumped 20 points in less than three days. Does that mean it’s too late to buy?

Cannabis reform remains bogged down in Washington and has taken a backseat to President Trump’s other priorities, but there are compelling reasons to buy low on cannabis.

This technique can work wonders if you are bold and are willing to go against traditional investing systems.

After three rough weeks in August, small caps have finally begun to stabilize around their 200-day moving average line.

I’d like to say blame for the weak performance rests fully on the shoulders of small-cap financials due to rising yields, commercial real estate mortgage default risk, etc.

But the truth is most sectors have been weak. Small-cap health care looks downright awful, with the Invesco S&P Small Cap Healthcare ETF (PSCH) hitting a new low for the year late last week.

Put a little money back to work. Our trend-following indicators are still bullish, and we’ve seen the Nasdaq and growth stocks show renewed strength in recent days. The market isn’t completely out of the woods, but there’s enough evidence to do a little new buying.

The stock market has been having quite the party over the past month. Since November 8, the date of the election, the S&P 500 is up by 4.8%. Small caps have crushed that performance, rising by almost 16% over the same timeframe.

Mike Cintolo discusses some encouraging action in the stock market this week.

• The Biggest Key to Understanding Cryptocurrency
• Important Investing Lessons from a Hedge Fund Pioneer
• The 3 Best Gold Mining Stocks to Buy Right Now
• 3 Cleantech Stocks Getting a Boost from the Climate Bill
• 5 REITs that Are Bucking the Housing Market Slowdown
• Using Options to Hedge Against Market Volatility
• How to Buy Warner Bros. Discovery (WBD) for Half the Price
• A Cheap Big Bank Stock to Buy Now
• The Best Way to Play High Interest Rates? Regional Banks
• 3 Growth Stocks with Good Charts

As Congress struggled with raising the debt ceiling, the excess of Federal spending over tax revenue totaled $459 billion through the first four months of the fiscal year (started October 1, 2022). Meanwhile, the strong dollar is a drag on multinational earnings. Today, we explore a fascinating company and stock that leverages artificial intelligence to accelerate biotech development.